These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 18958356

  • 21. Changes in the expression of cytokeratins and nuclear matrix proteins are correlated with the level of differentiation in human prostate cancer.
    Alberti I, Barboro P, Barbesino M, Sanna P, Pisciotta L, Parodi S, Nicolò G, Boccardo F, Galli S, Patrone E, Balbi C.
    J Cell Biochem; 2000 Sep 07; 79(3):471-85. PubMed ID: 10972984
    [Abstract] [Full Text] [Related]

  • 22. Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer.
    Mariani S, Salvatori L, Basciani S, Arizzi M, Franco G, Petrangeli E, Spera G, Gnessi L.
    J Urol; 2006 Jun 07; 175(6):2072-7; discussion 2077. PubMed ID: 16697805
    [Abstract] [Full Text] [Related]

  • 23. pS2 (TFF1) expression in prostate carcinoma: correlation with steroid receptor status.
    Abdou AG, Aiad HA, Sultan SM.
    APMIS; 2008 Nov 07; 116(11):961-71. PubMed ID: 19132993
    [Abstract] [Full Text] [Related]

  • 24. [Expressions of telomerase reverse transcriptase and vascular endothelial growth factor and their correlation in prostate cancer].
    Li X, Wang N, Zhang Y, Zhang SX, Lin Q, Tang J.
    Zhonghua Nan Ke Xue; 2005 Oct 07; 11(10):724-6, 730. PubMed ID: 16281501
    [Abstract] [Full Text] [Related]

  • 25. Human telomerase reverse transcriptase expression correlates with vascular endothelial growth factor-promoted tumor cell proliferation in prostate cancer.
    Tang J, Wang Z, Li X, Li J, Shi H.
    Artif Cells Blood Substit Immobil Biotechnol; 2008 Oct 07; 36(2):83-93. PubMed ID: 18437586
    [Abstract] [Full Text] [Related]

  • 26. Apoptosis-related gene expression in benign prostatic hyperplasia and prostate carcinoma.
    Iacopino F, Angelucci C, Lama G, Zelano G, La Torre G, D'Addessi A, Giovannini C, Bertaccini A, Macaluso MP, Martorana G, Sica G.
    Anticancer Res; 2006 Oct 07; 26(3A):1849-54. PubMed ID: 16827116
    [Abstract] [Full Text] [Related]

  • 27. CD151 protein expression predicts the clinical outcome of low-grade primary prostate cancer better than histologic grading: a new prognostic indicator?
    Ang J, Lijovic M, Ashman LK, Kan K, Frauman AG.
    Cancer Epidemiol Biomarkers Prev; 2004 Nov 07; 13(11 Pt 1):1717-21. PubMed ID: 15533898
    [Abstract] [Full Text] [Related]

  • 28. [Expression of nucleosomal binding protein 1 in normal prostate benign prostate hyperplasia, and prostate cancer and significance thereof].
    Song G, Zhou LQ, Weng M, He Q, He ZS, Hao JR, Pan BN, Na YQ.
    Zhonghua Yi Xue Za Zhi; 2006 Jul 25; 86(28):1962-5. PubMed ID: 17064590
    [Abstract] [Full Text] [Related]

  • 29. Down-regulation of p27(Kip 1) cyclin-dependent kinase inhibitor in prostate cancer: distinct expression in various prostate cells associating with tumor stage and grades.
    Nikoleishvili D, Pertia A, Tsintsadze O, Gogokhia N, Chkhotua A.
    Georgian Med News; 2007 Feb 25; (143):34-8. PubMed ID: 17404436
    [Abstract] [Full Text] [Related]

  • 30. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia.
    Soulitzis N, Karyotis I, Delakas D, Spandidos DA.
    Int J Oncol; 2006 Aug 25; 29(2):305-14. PubMed ID: 16820871
    [Abstract] [Full Text] [Related]

  • 31. [Expression and significance of clusterin in normal prostate, benign prostate hyperplasia and prostate cancer].
    Zhou LQ, Yang XZ, Zeng L, Liang LL, Yang XY, Ren L, Chung L, Zhang ZW, Na YQ, Gu FL, Guo YL.
    Zhonghua Wai Ke Za Zhi; 2003 Feb 25; 41(2):93-5. PubMed ID: 12783666
    [Abstract] [Full Text] [Related]

  • 32. [Expression of nucleostemin in prostate cancer tissues and its clinical significance].
    Liu RL, Xu Y, Zhang ZH, Wang M, Sun JT, Qi SY, Zhang Y, Li SZ.
    Zhonghua Nan Ke Xue; 2008 May 25; 14(5):418-22. PubMed ID: 18572860
    [Abstract] [Full Text] [Related]

  • 33. NeuroD1 expression in human prostate cancer: can it contribute to neuroendocrine differentiation comprehension?
    Cindolo L, Franco R, Cantile M, Schiavo G, Liguori G, Chiodini P, Salzano L, Autorino R, Di Blasi A, Falsaperla M, Feudale E, Botti G, Gallo A, Cillo C.
    Eur Urol; 2007 Nov 25; 52(5):1365-73. PubMed ID: 17126478
    [Abstract] [Full Text] [Related]

  • 34. Profiling protein markers associated with lymph node metastasis in prostate cancer by DIGE-based proteomics analysis.
    Pang J, Liu WP, Liu XP, Li LY, Fang YQ, Sun QP, Liu SJ, Li MT, Su ZL, Gao X.
    J Proteome Res; 2010 Jan 25; 9(1):216-26. PubMed ID: 19894759
    [Abstract] [Full Text] [Related]

  • 35. [Significance of MMP2 and MMP9 expression in prostate cancer].
    Zhang XY, Hong BF, Chen GF, Lu YL, Zhong M.
    Zhonghua Nan Ke Xue; 2005 May 25; 11(5):359-61, 364. PubMed ID: 15934460
    [Abstract] [Full Text] [Related]

  • 36. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer.
    Zhigang Z, Wenlv S.
    World J Surg Oncol; 2004 May 10; 2():13. PubMed ID: 15132743
    [Abstract] [Full Text] [Related]

  • 37. Lymph and blood vessel architecture in benign and malignant prostatic tissue: lack of lymphangiogenesis in prostate carcinoma assessed with novel lymphatic marker lymphatic vessel endothelial hyaluronan receptor (LYVE-1).
    Trojan L, Michel MS, Rensch F, Jackson DG, Alken P, Grobholz R.
    J Urol; 2004 Jul 10; 172(1):103-7. PubMed ID: 15201747
    [Abstract] [Full Text] [Related]

  • 38. Different perforin expression in peripheral blood and prostate tissue in patients with benign prostatic hyperplasia and prostate cancer.
    Tokmadžić VS, Tomaš MI, Sotošek S, Laškarin G, Dominović M, Tulić V, Dorđević G, Sustić A, Mrakovčić-Šutić I.
    Scand J Immunol; 2011 Oct 10; 74(4):368-76. PubMed ID: 21535078
    [Abstract] [Full Text] [Related]

  • 39. Changes in keratin expression during the development of benign prostatic hyperplasia.
    Xue Y, Smedts F, Umbas R, Aalders TW, Debruyne FM, de la Rosette JJ, Schalken JA.
    Eur Urol; 1997 Oct 10; 32(3):332-8. PubMed ID: 9358223
    [Abstract] [Full Text] [Related]

  • 40. Upregulation of erythropoietin receptor in human prostate carcinoma and high-grade prostatic intraepithelial neoplasia.
    Zhou T, Xu C, He M, Sun Y.
    Prostate Cancer Prostatic Dis; 2008 Oct 10; 11(2):143-7. PubMed ID: 17637760
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.